NASDAQ:ONTX Onconova Therapeutics (ONTX) Stock Price, News & Analysis → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free ONTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.67▼$1.0152-Week Range N/AVolume1.28 million shsAverage Volume96,681 shsMarket Capitalization$20.90 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesShort InterestSocial Media Get Onconova Therapeutics alerts: Email Address Ad Weiss RatingsThis is the best new way to score with AIIf you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects About Onconova Therapeutics Stock (NASDAQ:ONTX)Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.Read More Ad Weiss RatingsThis is the best new way to score with AIIf you thought that you missed your chance to score big on AI, I have great news. A rare second profit window is starting to open.Click now for the best way into the newest AI projects ONTX Stock News HeadlinesApril 4, 2024 | uk.investing.comOnconova and Trawsfynydd merge to form Traws PharmaApril 4, 2024 | finance.yahoo.comTraws Pharma Full Year 2023 Earnings: Beats ExpectationsApril 3, 2024 | msn.comNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with TrawsfynyddApril 2, 2024 | markets.businessinsider.comOnconova Acquires Trawsfynydd To Form Traws PharmaApril 2, 2024 | globenewswire.comTraws Pharma Announces New Employee Inducement GrantsMarch 12, 2024 | msn.comOnconova to Unveil New Rigosertib Study Results at Cancer Research MeetingMarch 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)March 8, 2024 | finance.yahoo.comOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024March 8, 2024 | globenewswire.comOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024February 13, 2024 | investing.comOnconova Therapeutics Inc (ONTX)January 23, 2024 | finance.yahoo.comOnconova Therapeutics, Inc. (ONTX)December 21, 2023 | benzinga.comOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and DatesDecember 12, 2023 | msn.comOnconova stock falls 10% on preclinical data for lymphoma drugDecember 12, 2023 | finance.yahoo.comOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell LymphomaDecember 8, 2023 | finance.yahoo.comOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sNovember 28, 2023 | finance.yahoo.comOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity ConferenceNovember 16, 2023 | finance.yahoo.comOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call TranscriptNovember 16, 2023 | finanznachrichten.deOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial ResultsNovember 7, 2023 | finance.yahoo.comOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023November 2, 2023 | benzinga.comOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLNovember 2, 2023 | finance.yahoo.comOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLOctober 19, 2023 | markets.businessinsider.comPromising Developments in Onconova Therapeutics’ Drug Narazaciclib Bolster Buy Rating: An AnalysisOctober 19, 2023 | finance.yahoo.comPromising Preclinical Narazaciclib Data Presented at MCL MeetingOctober 12, 2023 | marketwatch.comOnconova Therapeutics Shares Rise 12% On Skin Cancer Treatment DataSee More Headlines Receive ONTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today5/16/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ONTX CUSIPN/A CIK1130598 Webwww.onconova.com Phone(267) 759-3680Fax267-759-3681Employees16Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,960,000.00 Net Margins-8,930.97% Pretax Margin-8,930.97% Return on Equity-95.43% Return on Assets-61.19% Debt Debt-to-Equity RatioN/A Current Ratio2.79 Quick Ratio2.79 Sales & Book Value Annual Sales$230,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / BookN/AMiscellaneous Outstanding Shares21,000,000Free Float20,310,000Market Cap$20.90 million OptionableOptionable Beta1.38 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Steven M. Fruchtman M.D. (Age 73)CEO, President & Director Comp: $907.86kMr. Mark Patrick Guerin CPA (Age 55)CFO & COO Comp: $629.27kDr. Victor Moyo M.D.Chief Medical OfficerKey CompetitorsOrgenesisNASDAQ:ORGSMEI PharmaNASDAQ:MEIPLumos PharmaNASDAQ:LUMOAlaunos TherapeuticsNASDAQ:TCRTSynlogicNASDAQ:SYBXView All Competitors ONTX Stock Analysis - Frequently Asked Questions Should I buy or sell Onconova Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONTX shares. View ONTX analyst ratings or view top-rated stocks. What is Onconova Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for Onconova Therapeutics' shares. Their ONTX share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. View analysts price targets for ONTX or view top-rated stocks among Wall Street analysts. When is Onconova Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ONTX earnings forecast. How were Onconova Therapeutics' earnings last quarter? Onconova Therapeutics, Inc. (NASDAQ:ONTX) posted its earnings results on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.06 million. Onconova Therapeutics had a negative net margin of 8,930.97% and a negative trailing twelve-month return on equity of 95.43%. During the same quarter in the previous year, the company earned ($0.45) EPS. When did Onconova Therapeutics' stock split? Shares of Onconova Therapeutics reverse split on Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Onconova Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM). This page (NASDAQ:ONTX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Onconova Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.